Boothbay Fund Management’s Jade Biosciences JBIO Stock Holding History

Boothbay Fund Management’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Sell	112,703 -27,265	-19%	-$569K	0.03%	616
2026 Q1	$1.97M	Buy	139,968 +58,820	+72%	+$852K	0.03%	631
2025 Q4	$1.25M	Buy	+81,148	New	+$952K	0.02%	722
2024 Q4	–	Sell	-2,795	Closed	-$204K	–	1495
2024 Q3	$204K	Sell	2,795 -358	-11%	-$23.1K	﹤0.01%	1393
2024 Q2	$183K	Buy	3,153 +358	+13%	+$237K	﹤0.01%	1303
2024 Q1	$2.89M	Buy	+2,795	New	+$2.13M	0.06%	384
2023 Q2	–	Sell	-1,131	Closed	-$798K	–	1808
2023 Q1	$798K	Buy	1,131 +393	+53%	+$326K	0.02%	1095
2022 Q4	$756K	Sell	738 -284	-28%	-$206K	0.02%	1015
2022 Q3	$593K	Buy	+1,022	New	+$682K	0.01%	1140

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's JBIO Position: Q2 2026 in Review

Boothbay Fund Management reduced its Jade Biosciences (JBIO) stake by 19% in Q2 2026, selling an estimated $569K and leaving 112,703 shares worth $2.5M. The position accounts for 0.03% of the portfolio, ranked #616.

Boothbay Fund Management first reported a position in JBIO in Q3 2022 and has held it in 9 quarters since. The position peaked at $2.89M in Q1 2024. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

Boothbay Fund Management held 112,703 shares of Jade Biosciences worth $2.5M as of Q2 2026.
Boothbay Fund Management sold 27,265 Jade Biosciences shares in Q2 2026, an estimated $569K.
Jade Biosciences made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #616 holding.
Boothbay Fund Management first reported a position in Jade Biosciences in Q3 2022 and has held it in 9 quarters since.
Boothbay Fund Management's Jade Biosciences position peaked at $2.89M in Q1 2024.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.